Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes

Internal Medicine

Volumn 56, Issue 6, 2017, Pages 597-604

  Tosaki, Takahiro ^a   Kamiya, Hideki ^b   Himeno, Tatsuhito ^b   Kato, Yoshiro ^b   Kondo, Masaki ^b   Toyota, Kaori ^a   Nishida, Tomoyo ^a   Shiroma, Megumi ^a   Tsubonaka, Kaori ^a   Asai, Hitomi ^a   Moribe, Miho ^a   Nakaya, Yuki ^a   Nakamura, Jiro ^b  

^a TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glycemic control; Oral hypoglycemic agent; Renal function; SGLT2 inhibitor; Visceral fat

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; ASPARTATE AMINOTRANSFERASE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GAMMA GLUTAMYLTRANSFERASE; GLIMEPIRIDE; GLINIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; METFORMIN; PIOGLITAZONE; TOFOGLIFLOZIN; UNCLASSIFIED DRUG; URIC ACID; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CYSTITIS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPHAGIA; HYPOGLYCEMIA; INTRAPERITONEAL FAT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRURITUS; SYSTOLIC BLOOD PRESSURE; URINARY ALBUMIN CREATININE RATIO; URINE LEVEL; WAIST CIRCUMFERENCE; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; INTRAABDOMINAL FAT; KIDNEY FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; BODY COMPOSITION; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INTRA-ABDOMINAL FAT; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; THIOPHENES;

EID: 85015840398     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.56.7196     Document Type: Article

References (24)

1. Kashiwagi A, Kazuta K, Yoshida S, Nagase I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 5: 382-391, 2014.
2. Nishimura R, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol 14: 11, 2015.
3. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 13: 65, 2014.
4. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 6: 587-590, 2015.
5. Ida M, Hirata M, Odori S, et al. Early changes of abdominal adi posity detected with weekly dual bioelectrical impedance analysis during calorie restriction. Obesity 21: 350-353, 2013.
6. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223-2233, 2010.
7. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 29: 2137-2139, 2006.
8. Roden M, Weng J, Eilbracht J, et al; EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1: 208-219, 2013.
9. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab 16: 1102-1110, 2014.
10. Wilding JP, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications 29: 438-444, 2015.
11. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16: 457-466, 2014.
12. Kashiwagi A, Kazuta K, Takinami Y, Yoshida S, Utsuno A, Nagase I. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetology International 6: 8-18, 2015.
13. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97: 1020-1031, 2012.
14. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941-950, 2013.
15. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 727: 66-74, 2014.
16. Muramoto A, Matsushita M, Kato A, et al. Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract 8: 466-475, 2013.
17. Takahara M, Shiraiwa T, Matsuoka TA, Katakami N, Shimomura I. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr J 62: 77-86, 2015.
18. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124: 509-514, 2014.
19. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity 20: 1645-1652, 2012.
20. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587-597, 2014.
21. Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 9: e100777, 2014.
22. Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 15: 403-409, 2013.
23. Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35: 391-404, 2014.
24. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT 2 inhibitors. Diabetes Care 38: 1638-1642, 2015.